Compare Inovio Pharmaceuticals Inc (INO) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Kroger Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Kroger Co trades at $58 (market cap $35.75B). The key difference: Kroger Co is far larger — about 400.5× Inovio Pharmaceuticals Inc's market cap, and Kroger Co pays a 2.47% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | KR | |
|---|---|---|
Market Cap | $89.27M | $35.75B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $75.60 |
52-Week Low | $1.05 | $55.53 |
Enterprise Value | $60.28M | $55.85B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Kroger (KR) trades at $58.39, down 0.73% on the day, with a bearish technical signal and mixed earnings history. The company maintains stable revenue near $147 billion (2025) and recently announced a $1.65 billion acquisition of Giant Eagle (Reuters, July 1, 2026). Cash flow from operations remains strong at $5.79 billion, though net income margin is thin at 0.71%.
Outlook: KR offers value with low P/S (0.25) and dividend yield, but faces margin pressure and integration risks from acquisitions. Analyst consensus is bullish with a $68.63 price target, though technical weakness and competitive threats warrant caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
